Bermingham Nessan 4
4 · Intellia Therapeutics, Inc. · Filed Dec 8, 2017
Insider Transaction Report
Form 4
Bermingham Nessan
DirectorPresident & CEO10% Owner
Transactions
- Sale
Common Stock
2017-12-07$21.05/sh−103,574$2,180,378→ 579,959 total - Sale
Common Stock
2017-12-06$20.28/sh−99,033$2,008,191→ 696,000 total - Sale
Common Stock
2017-12-06$20.84/sh−12,467$259,810→ 683,533 total - Sale
Common Stock
2017-12-07$21.46/sh−27,566$591,489→ 552,393 total - Sale
Common Stock
2017-12-08$20.82/sh−94,143$1,960,151→ 458,250 total
Footnotes (5)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $19.70 to $20.69. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
- [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.70 to $21.12. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
- [F3]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.33 to $21.32. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
- [F4]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $21.33 to $21.65. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
- [F5]The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.51 to $21.48. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.